The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy

被引:70
作者
Carrier, Lucie [1 ,2 ,3 ]
Schlossarek, Saskia [1 ]
Willis, Monte S. [4 ,5 ]
Eschenhagen, Thomas [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Cardiovasc Res Ctr, Inst Expt & Clin Pharmacol & Toxicol, D-20246 Hamburg, Germany
[2] INSERM, Inst Myol, U974, F-75013 Paris, France
[3] Univ Paris 06, UMR S974, CNRS,IFR14, UMR7215,Inst Myol, F-75013 Paris, France
[4] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA
[5] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA
关键词
Hypertrophy; Cardiomyopathy; Ubiquitin-proteasome system; Nonsense-mediated mRNA decay; BINDING-PROTEIN-C; SPLICE DONOR SITE; CARDIAC-HYPERTROPHY; PROTEOLYTIC FUNCTION; SEPTAL HYPERTROPHY; DIAGNOSTIC-VALUE; IN-VIVO; MUTATIONS; GENE; EXPRESSION;
D O I
10.1093/cvr/cvp247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiomyopathies represent an important cause of cardiovascular morbidity and mortality due to heart failure, arrhythmias, and sudden death. Most forms of hypertrophic cardiomyopathy (HCM) are familial with an autosomal-dominant mode of inheritance. Over the last 20 years, the genetic basis of the disease has been largely unravelled. HCM is considered as a sarcomeropathy involving mutations in sarcomeric proteins, most often beta-myosin heavy chain and cardiac myosin-binding protein C. 'Missense' mutations, more common in the former, are associated with dysfunctional proteins stably integrated into the sarcomere. 'Nonsense' and frameshift mutations, more common in the latter, are associated with low mRNA and protein levels derived from the diseased allele, leading to haploinsufficiency of the remaining healthy allele. The two quality control systems responsible for the removal of the affected mRNAs and proteins are the nonsense-mediated mRNA decay (NMD) and the ubiquitin-proteasome system (UPS), respectively. This review discusses clinical and genetic aspects of HCM and the role of NMD and UPS in the regulation of mutant proteins, evidence for impairment of UPS as a pathogenic factor, as well as potential therapies for HCM.
引用
收藏
页码:330 / 338
页数:9
相关论文
共 92 条
[21]   The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy [J].
Cuda, G ;
Fananapazir, L ;
Epstein, ND ;
Sellers, JR .
JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 1997, 18 (03) :275-283
[22]   FAMILIAL HYPERTROPHIC CARDIOMYOPATHY - MICROSATELLITE HAPLOTYPING AND IDENTIFICATION OF A HOT-SPOT FOR MUTATIONS IN THE BETA-MYOSIN HEAVY-CHAIN GENE [J].
DAUSSE, E ;
KOMAJDA, M ;
FETLER, L ;
DUBOURG, O ;
DUFOUR, C ;
CARRIER, L ;
WISNEWSKY, C ;
BERCOVICI, J ;
HENGSTENBERG, C ;
ALMAHDAWI, S ;
ISNARD, R ;
HAGEGE, A ;
BOUHOUR, JB ;
DESNOS, M ;
BECKMANN, J ;
WEISSENBACH, J ;
SCHWARTZ, K ;
GUICHENEY, P .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2807-2813
[23]   Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy [J].
Deinum, J ;
van Gool, JMG ;
Kofflard, MJM ;
ten Cate, FJ ;
Danser, AHJ .
HYPERTENSION, 2001, 38 (06) :1278-1281
[24]   Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice [J].
Eijssen, L. M. T. ;
van den Bosch, B. J. C. ;
Vignier, N. ;
Lindsey, P. J. ;
van den Burg, C. M. M. ;
Carrier, L. ;
Doevendans, P. A. ;
van der Vusse, G. J. ;
Smeets, H. J. M. .
GENOMICS, 2008, 91 (01) :52-60
[25]   Hypertrophic cardiomyopathy [J].
Elliott, P ;
McKenna, WJ .
LANCET, 2004, 363 (9424) :1881-1891
[26]   Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases [J].
Elliott, Perry ;
Andersson, Bert ;
Arbustini, Eloisa ;
Bilinska, Zofia ;
Cecchi, Franco ;
Charron, Philippe ;
Dubourg, Olivier ;
Hl, Uwe Ku R. ;
Maisch, Bernhard ;
McKenna, William J. ;
Monserrat, Lorenzo ;
Pankuweit, Sabine ;
Rapezzi, Claudio ;
Seferovic, Petar ;
Tavazzi, Luigi ;
Keren, Andre .
EUROPEAN HEART JOURNAL, 2008, 29 (02) :270-276
[27]   Genetic factors in aminoglycoside toxicity [J].
Fischel-Ghodsian, N .
PHARMACOGENOMICS, 2005, 6 (01) :27-36
[28]   Biomolecular interactions between human recombinant β-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy [J].
Flavigny, J ;
Robert, P ;
Camelin, JC ;
Schwartz, K ;
Carrier, L ;
Berrebi-Bertrand, I .
CARDIOVASCULAR RESEARCH, 2003, 60 (02) :388-396
[29]   COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes [J].
Flavigny, J ;
Souchet, M ;
Sébillon, P ;
Berrebi-Bertrand, I ;
Hainque, B ;
Mallet, A ;
Bril, A ;
Schwartz, K ;
Carrier, L .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 294 (02) :443-456
[30]  
Fougerousse F, 1998, CIRC RES, V82, P130